Lexent Bio Announces Use of its Liquid Biopsy Assay, Confera Dx, in a Peer-Reviewed Paper Published in the Journal Molecular Cancer Therapeutics

MLA

“Lexent Bio Announces Use of Its Liquid Biopsy Assay, Confera Dx, in a Peer-Reviewed Paper Published in the Journal Molecular Cancer Therapeutics.” Cancer Weekly, 26 May 2020, p. 88. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.624764665&authtype=sso&custid=ns315887.

APA

Lexent Bio Announces Use of its Liquid Biopsy Assay, Confera Dx, in a Peer-Reviewed Paper Published in the Journal Molecular Cancer Therapeutics. (2020, May 26). Cancer Weekly, 88.

Chicago

Cancer Weekly. 2020. “Lexent Bio Announces Use of Its Liquid Biopsy Assay, Confera Dx, in a Peer-Reviewed Paper Published in the Journal Molecular Cancer Therapeutics,” May 26. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.624764665&authtype=sso&custid=ns315887.